Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial

NCT05382741 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

182

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Stage IV
No Evidence of Disease State

Interventions

DRUG: Durvalumab Injection for intravenous use 500 mg vial solution for infusion
DRUG: Regorafenib 30 mg capsules

Sponsor

Ospedale Policlinico San Martino

Collaborators

[object Object]
[object Object]
[object Object]